SELFPOCNAD

Development of a Point of Care microfluidic chip unit and self-sampling device for cervical cancer screening and platform technology for Nucleic Acid Detection at the Point of Care

Coordinatore	PRETECT AS    more  Organization address address: INDUSTRIVEIEN 8 city: KLOKKARSTUA postcode: 3490 contact info Titolo: Mr. Nome: Morten Cognome: Hagen Email: send email Telefono: +47 32798800 Fax: +47 32798801
Nazionalità Coordinatore	Norway [NO]
Totale costo	1˙490˙878 €
EC contributo	1˙171˙731 €
Programma	FP7-SME Specific Programme "Capacities": Research for the benefit of SMEs
Code Call	FP7-SME-2010-1
Funding Scheme	BSG-SME
Anno di inizio	2010
Periodo (anno-mese-giorno)	2010-10-01   -   2012-12-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	PRETECT AS  Organization address address: INDUSTRIVEIEN 8 city: KLOKKARSTUA postcode: 3490 contact info Titolo: Mr. Nome: Morten Cognome: Hagen Email: send email Telefono: +47 32798800 Fax: +47 32798801	NO (KLOKKARSTUA)	coordinator	449˙071.50
2	IMS RESEARCH BV  Organization address address: EINSTEINSTRAAT 14 city: ALMELO postcode: 7601 PR contact info Titolo: Mr. Nome: Nol Cognome: Brouwers Email: send email Telefono: +31 546 805580 Fax: +31 546 805587	NL (ALMELO)	participant	246˙485.75
3	"DELTA DANSK ELEKTRONIK, LYS & AKUSTIK"  Organization address address: VENLIGHEDSVEJ 4 city: HERSHOLM postcode: 2970 contact info Titolo: Mr. Nome: Morten Cognome: Bech Email: send email Telefono: +45 72 19 44 04 Fax: +45 72 19 40 01	DK (HERSHOLM)	participant	224˙930.00
4	microLIQUID sl  Organization address address: Av. Uribarri 19-1 city: Arrasate-Mondragon postcode: 20500 contact info Titolo: Mr. Nome: Borja Cognome: Barredo Email: send email Telefono: +34 610 220 406 Fax: +34 943 712 223	ES (Arrasate-Mondragon)	participant	159˙500.66
5	European Cervical Cancer Association  Organization address address: rue Jourdan 121 city: Brussels postcode: 1060 contact info Titolo: Dr. Nome: Philip Cognome: Davies Email: send email Telefono: +32 2 538 2833 Fax: +32 2 538 5833	BE (Brussels)	participant	47˙200.00
6	Nor-Tek Teknologisenter AS  Organization address address: GAUSTADALLEEN 21 city: OSLO postcode: 349 contact info Titolo: Mr. Nome: Rune Cognome: Nilsen Email: send email Telefono: +47 95 96 54 54 Fax: +47 22 60 44 27	NO (OSLO)	participant	18˙072.00
7	IKERLAN S.COOP.  Organization address address: Paseo J.M. Arizmendiarrieta 2 city: MONDRAGON postcode: 20500 contact info Titolo: Dr. Nome: Chris Cognome: Merveille Email: send email Telefono: +34 943 71 24 00 Fax: +34 943 796 944	ES (MONDRAGON)	participant	14˙360.00
8	HOGSKOLEN I VESTFOLD  Organization address address: RAVEIEN 197 city: TONSBERG postcode: 3103 contact info Titolo: Mr. Nome: Bjørnar Cognome: Thorsen Email: send email Telefono: +47 33 03 11 51 Fax: +47 33 03 11 03	NO (TONSBERG)	participant	12˙112.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'In SelfPOCNAD, we propose to develop an industrial prototype for a rapid (“same day”) Cervical Cancer screening of self-taken patient samples. The industrial prototype will only include enough sample from the self-taken sample in order not to risk any clogging of the sample preparation chip. The first industrial prototype will include the detection of oncogenic E6/E7 mRNA from in total 9 HPV types with an option to detect up to 19 HPV types based on detection developed for Pre-Tect HPV-Proofer laboratory kit, Nucleic Acid Sequence Based Amplification. Introduction of SelfPOCNAD at Point of Care is expected to significantly improve compliance of women with Cervical Cancer screening programs Increased compliance of women with the ICC screening programs will drastically decrease the ICC incidence and save lives. ICC is the second most common cancer in women. Each year, there are over 470,000 new cases globally. Of these, 33,000 are in the EU. Once the disease is established, it is hard to cure, so each year 233,000 women die - 15,000 in the EU . After breast cancer, it is the second-most-common cancer amongst women. However, this is a preventable and treatable disease, if detected in the early stages. Some EU member states have well-organised screening and effective prevention programmes. But better compliance with screening, especially in New Member States could save the lives of 3-5,000 European women p.a.'